Clinical trial
Inhaled Hydrogen Therapy's Effect on Early Recurrences of Atrial Fibrillation Post-ablation. Phase II, Multicenter, Randomized, Controlled, Open-label Clinical Trial
NCT07928622 is registered in ClinicalTrials.gov with University Hospital, Grenoble as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Inhaled Hydrogen Therapy's Effect on Early Recurrences of Atrial Fibrillation Post-ablation. Phase II, Multicenter, Randomized, Controlled, Open-label Clinical Trial
- Lead sponsor
- University Hospital, Grenoble
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- January 31, 2027
- Completion date
- September 30, 2029
- Enrollment
- 124 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
atrial fibrillation ablation
Arms
As registered; 2 arms.
-
Standard of care
patients treated with usual care (Standard of Care)
-
H2
patient treated with inhaled hydrogen therapy during the perioperative period
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Effectiveness of inhaled hydrogen therapy on early recurrences of atrial fibrillation post-ablation and on the improvement of quality of life at 3 months
Composite binary endpoint, reported as the number of participants meeting both criteria: (1) no early recurrence during the blanking period (first 3 months after ablation), where recurrence is defined as any episode of atrial fibrillation, atrial flutter or atrial tachycardia lasting at least 30 seconds; AND (2) improvement in quality of life, defined as an improvement in quality of life, defined as an increase of at least 5 points in the AFEQT overall score (range 0-100; higher scores indicate better quality of life) between baseline and 3 months.
Lead sponsor's other trials
University Hospital, Grenoble, most recent start first.
+832 more trials See the organization page